6652 Stock Overview
Eusol Biotech Co.,Ltd. focuses on developing drugs for unmet medical needs.
EUSOL Biotech Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$8.30|
|52 Week High||NT$24.45|
|52 Week Low||NT$8.08|
|1 Month Change||-7.78%|
|3 Month Change||-33.60%|
|1 Year Change||-64.68%|
|3 Year Change||-60.48%|
|5 Year Change||n/a|
|Change since IPO||-80.87%|
Recent News & Updates
We Think EUSOL Biotech (GTSM:6652) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|6652||TW Pharmaceuticals||TW Market|
Return vs Industry: 6652 underperformed the TW Pharmaceuticals industry which returned 3% over the past year.
Return vs Market: 6652 underperformed the TW Market which returned 0.7% over the past year.
|6652 Average Weekly Movement||4.9%|
|Pharmaceuticals Industry Average Movement||5.3%|
|Market Average Movement||4.6%|
|10% most volatile stocks in TW Market||8.3%|
|10% least volatile stocks in TW Market||2.1%|
Stable Share Price: 6652 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 6652's weekly volatility (5%) has been stable over the past year.
About the Company
Eusol Biotech Co.,Ltd. focuses on developing drugs for unmet medical needs. Its pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for repairing neuron function; and SM-1, a 3-in-1 capsule containing 3 commercial drugs with sedative effect.
EUSOL Biotech Fundamentals Summary
|6652 fundamental statistics|
Is 6652 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6652 income statement (TTM)|
|Cost of Revenue||NT$0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.90|
|Net Profit Margin||0.00%|
How did 6652 perform over the long term?See historical performance and comparison
Is EUSOL Biotech undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 6652's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6652's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: 6652 is unprofitable, so we can't compare its PE Ratio to the TW Pharmaceuticals industry average.
PE vs Market: 6652 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6652's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6652 is overvalued based on its PB Ratio (2.6x) compared to the TW Pharmaceuticals industry average (2x).
How is EUSOL Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as EUSOL Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has EUSOL Biotech performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6652 is currently unprofitable.
Growing Profit Margin: 6652 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6652 is unprofitable, but has reduced losses over the past 5 years at a rate of 8.9% per year.
Accelerating Growth: Unable to compare 6652's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6652 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.6%).
Return on Equity
High ROE: 6652 has a negative Return on Equity (-28.41%), as it is currently unprofitable.
How is EUSOL Biotech's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 6652's short term assets (NT$305.0M) exceed its short term liabilities (NT$20.1M).
Long Term Liabilities: 6652's short term assets (NT$305.0M) exceed its long term liabilities (NT$752.0K).
Debt to Equity History and Analysis
Debt Level: 6652 is debt free.
Reducing Debt: 6652 has no debt compared to 5 years ago when its debt to equity ratio was 0.08%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6652 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6652 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 14.6% each year
What is EUSOL Biotech current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6652's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6652's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6652's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6652's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 6652 has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Jin-Ding Huang, PhD, serves as Director and Chief Scientific Officer at Senhwa Biosciences, Inc. since 2022. Jin-Ding Huang serves as Chief Executive Officer of EUSOL Biotech Co., Ltd. Jin-Ding Huang is Vi...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
EUSOL Biotech Co., Ltd.'s employee growth, exchange listings and data sources
- Name: EUSOL Biotech Co., Ltd.
- Ticker: 6652
- Exchange: TPEX
- Founded: 2005
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: NT$1.137b
- Shares outstanding: 137.00m
- Website: https://www.eusol-biotech.com
Number of Employees
- EUSOL Biotech Co., Ltd.
- No.135 Minsheng East Road
- 6th Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/16 00:00|
|End of Day Share Price||2022/05/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.